Wednesday Software Fails: Infusion pumps giving incorrect dosages

CareFusion runs into more 'deadly' trouble with infusion pump

 CareFusion's ($CFN) Alaris pump is again the subject of a recall, earning the FDA's most serious designation over a software problem that can muddle scheduled infusions and put patients at risk.

The pump, designed to deliver medicines and fluids in a hospital setting, may fail to delay an infusion despite being programmed to do so, the company said, and the device is prone to missing multidose administrations depending on when they're inputted. The FDA designated the issue a Class I recall, reserved for device malfunctions that could lead to serious injury or death.

CareFusion first informed customers of the problem last month, promising to contact each individually to schedule a software installation that would remedy the issue. The company said it had not received any reports of adverse events tied to the software. The FDA asks customers to disclose any such problems through its MedWatch system.

The malfunction makes for CareFusion's fourth Alaris-related Class I recall in two years, following issues with the device's keyboard, peripheral attachments and power supply. In October, the San Diego company endured the agency's most serious designation over a problem with its AVEA ventilators, which tended to underreport volume on their neonatal setting.

CareFusion gets the majority of its revenue from infusion systems and respiratory technologies, part of a combined business that slipped 2% to bring in $571 million in sales last quarter. Overall, the company boosted its revenue 7% to $968 million in Q3 thanks to double-digit growth in its disposables segment.

I wonder how the software was tested. How does it differ from the hospital setting? If we can find out the scenario on the faulty devices then we can figure out ways to handle these scenarios.

For systems that affect people it might be good to add a few more resources to find out more use cases that users might experience as an underdose or overdose could result in death

Happy Testing!



Leave a Reply

Your email address will not be published. Required fields are marked *

I accept that my given data and my IP address is sent to a server in the USA only for the purpose of spam prevention through the Akismet program.More information on Akismet and GDPR.